Researchers made a gel that slowly releases tiny cancerâspecific peptides together with two immuneâboosting substances, one of which is thymosinâalphaâ1. In mice with liver metastases, this gel plus standard checkpointâinhibitor drugs (PDâ1 and CTLAâ4 blockers) sparked a strong attack by a special type of killer Tâcell (CD8âșCD69âș) and reduced suppressive Tâcells, leading to tumor shrinkage and lasting immunity without obvious side effects. The work is still in animal models, so it isnât a readyâtoâuse protocol for individuals yet.
Distler. Max E ME; Teplensky. Michelle H MH; Bujold. Katherine E KE; Kusmierz. Caroline D CD; Evange...
Scientists made tiny DNA structures called dendrons that can grab onto peptides like thymosinâalphaâ1 and help cells take them in much better. In lab tests, these DNA dendrons got inside most cells quickly and delivered over 20 times more material than regular DNA strands, boosting the peptideâs activity. While promising, the technique is still earlyâstage and not yet ready for personal use.
A 65âyearâold woman with severe COVIDâ19 got better after receiving three infusions of umbilicalâcord stem cells plus daily thymosinâalphaâ1 shots, antibiotics, and standard care. Her inflammation markers and lung scans improved, she left the ICU, and her virus test turned negative after four days.
In mice, the health of the thymus (the organ that makes immune signals) influences how breast cancer grows and spreads. Two thymusârelated proteins, PTMα and TÎČ15b1, change their levels when the thymus is damaged, and tweaking these proteins can speed up or slow down tumor growth at different stages. The study suggests that thymusâderived signals, like the peptide thymosinâalphaâ1, might affect cancer behavior, but the work is still early and done only in animals.
A 104âyearâold man with liver cancer was given occasional thymosinâalphaâ1 shots along with Chinese herbs and nutrition support, and he lived for at least 27 months without tumorârelated complications, showing good tolerance to the treatment.
Wu. Yan Y; He. Lingling L; Guo. Yongping Y; Wang. Niansong N
In dialysis patients who catch the Omicron COVIDâ19 variant, having diabetes, low bloodâoxygen levels, or high inflammation (CRP) makes severe illness more likely, while good oxygen levels help. If they become very sick, breathing trouble predicts death, but two drugsâthymosinâalphaâ1 (thymalfasin) and the Chinese formula Tanreqingâwere linked to higher chances of leaving the hospital alive, especially Tanreqing. These findings mainly apply to kidneyâdialysis patients, not the general public.
Shi. Fang F; Qiu. Huiping H; Yan. Jinjin J; Ke. Changlin C; Li. Yao Y
A study in lung cancer patients showed that giving thymosinâalphaâ1 (thymalfasin) lowered the number of immuneâsuppressing cells (MDSCs) in the blood and tumor tissue, which could help the body fight the cancer better.
A 31âyearâold woman gave birth early and got very sick with COVIDâ19ârelated lung failure. She was treated with a mix of drugs, including the immuneâboosting peptide thymosinâα1, and needed a heartâlung machine (ECMO) after delivery. She was weaned off ECMO and recovered well.
A study in 400 colorectalâcancer surgery patients found that giving thymosinâalphaâ1 (thymalfasin) at 1.6âŻmg twice or three times a week lowered infection rates, reduced postâsurgery complications, and improved immune markers and diseaseâfree survival, but the two dosing schedules performed similarly.
Guo. Xiao-Ling XL; Wang. Kun K; Jin. Jie J; Dai. Li-Li LL
In people who got COVIDâ19 despite being fully vaccinated, giving the antibody cocktail BRIIâ196/BRIIâ198 early helped severely ill patients clear the virus faster and raise their own antibody levels, but it didnât help those with milder disease. Adding the peptide thymosinâalphaâ1 (thymalfasin) for patients with low lymphocyte counts didnât speed up immuneâcell recovery.
Xu. Yunlong Y; Jiang. Yanjun Y; Wang. Lin L; Huang. Jiahua J; Wen. Junmao J; Lv. Hang H; Wu. Xiaoli...
In mice, giving thymosinâalphaâ1 (a peptide that boosts the immune system) reduced pain caused by inflammation, lowered harmful inflammatory chemicals in the skin and spinal cord, and calmed down brainâimmune cells called microglia. It also helped balance chemicals that control nerve signals. The work shows the peptide can ease inflammatory pain in animals, but itâs still earlyâstage and not proven in people.
In lab tests, the peptide thymosinâalphaâ1 slowed the growth and movement of lung cancer cells and boosted the cells' own antioxidant defenses, but it didnât trigger cell death. These effects were seen at relatively high concentrations that are not comparable to typical human supplement doses.
He. Gang G; Chuai. Xia X; Liang. Dan D; Chen. Chunyu C; Hu. Changzheng C; Ke. Changwen C; Ke. Bixia...
A person with a weak immune system had a silent COVIDâ19 infection for over two months and was given thymosinâalphaâ1 (Thymalfasin) every other day, plus an antiviral drug. Even with this treatment, they never developed COVIDâ19 antibodies and showed low numbers of several key immune cells, suggesting the peptide didnât fix the immune gaps in this case.
Huang. Jiahua J; Jiang. Huaqing H; Pan. Meijun M; Jiang. Yanjun Y; Xie. Lijin L
In a mouse study, the immuneâboosting peptide thymosinâalphaâ1 reduced pain caused by inflammation, likely by lowering inflammatory chemicals and blocking a painârelated signaling pathway in the spinal cord.
Adding thymosinâalphaâ1 to the standard HBV drug entecavir was safe but didnât clearly improve liver outcomes or survival in people with compensated cirrhosis, though there was a tiny drop in liver cancer cases.
A study in newborn mice found that giving the immuneâboosting peptide thymosinâalphaâ1 under the skin helped the kidsâ brains grow more new cells and improved their learning later on, likely because it nudged the immune system toward a Th1âtype response and raised brainâsupporting growth factors. The effect also protected the brain from damage caused by an infectionâmimic. However, the work was done in very young mice, not humans, and no dosing or safety info for people is provided, so itâs not a readyâtoâuse protocol for most biohackers.
Armirotti. Andrea A; Tomati. Valeria V; Matthes. Elizabeth E; Veit. Guido G; Cholon. Deborah M DM; P...
The study shows that the peptide thymosinâalphaâ1 does not help fix the faulty CFTR protein that causes cystic fibrosis, even when different labs and handling methods are used. It also found that another drug, cysteamine, didnât work either and could be harmful when mixed with certain antioxidants.
Du. Dexi D; Song. Tao T; Dai. Hui H; Jing. Zhao Z; Chen. Peng P; Wu. Shixiu S
A small study gave cancer patients a combo of precise radiation and a peptide called thymosinâalphaâ1. About half of the treated spots stopped growing, and the treatment was safe with no severe side effects, but overall survival was still limited (about 5 months). The results hint that the peptide might boost the immune response when paired with radiation, but itâs only been tested in advanced esophageal cancer, not in healthy people.
Romani. Luigina L; Oikonomou. Vasilis V; Moretti. Silvia S; Iannitti. Rossana G RG; D'Adamo. Maria C...
The study shows that thymosinâalphaâ1, a peptide already used safely as an immuneâboosting drug, can both calm inflammation and help the faulty CFTR protein work better in cystic fibrosis models, suggesting it might one day be a singleâdrug treatment for that disease.
Giacomini. Elena E; Rizzo. Fabiana F; Etna. Marilena P MP; Cruciani. Melania M; Mechelli. Rosella R;...
The study found that people with relapsingâremitting multiple sclerosis have low levels of the peptide thymosinâalphaâ1, and adding this peptide to immune cells in the lab lowered inflammatory signals while boosting antiâinflammatory ones, especially by growing special B cells that produce ILâ10. This suggests thymosinâalphaâ1 can shift the immune system toward a calmer state in MS patients.